CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...